CRISPR-Cas9 efficiently removes the GAA repeat expansion from intron 1 in FRDA patient hematopoietic stem and progenitor cells, thus leading to increased frataxin expression and mitochondrial function [57]. Here, FXN is linked to Friedreich ataxia.